News Archives - Page 2 of 26 - BillionDollarClub

TuesdaySep 01, 2026 9:30 am

BillionDollarBreaks – BOXABL Inc. (NASDAQ: BXBL) Co-Founder Discusses Manufacturing Strategy, Phase Two Products on Bell2Bell Podcast

BOXABL (NASDAQ: BXBL) Co-Founder and Co-CEO Galiano Tiramani joined IBN’s Bell2Bell Podcast to discuss the company modular building system, manufacturing strategy and plans to scale housing production. Tiramani highlighted BOXABL’s approach to applying assembly-line mass production to housing, its shipping model designed to expand the reach of centralized manufacturing and its 400,000 square feet of manufacturing space. He also discussed the company shift from a heavy focus on research and engineering toward sales and deployment, including the planned rollout of its Phase Two product lineup, as well as BOXABL’s Nasdaq listing, vertical integration plans and long-term growth strategy. To view…

TuesdaySep 01, 2026 9:00 am

BillionDollarBreaks – BOXABL Inc. (NASDAQ: BXBL) Enters Multiyear Agreement for Up to 1,500 Homes

BOXABL (NASDAQ: BXBL) announced a multiyear purchase agreement with LC Vegas Acquisitions, LLC contemplating the purchase of up to 1,500 BOXABL homes over three years, representing the company largest announced residential purchase arrangement to date. Purchases are expected to occur in phases at approximately 500 homes annually, subject to project schedules, site readiness, regulatory approvals and other conditions. The agreement does not require any purchases to be made and contemplated units may be modified, delayed, reduced or terminated under its terms. To view the full press release, visit https://ibn.fm/KOlTq About BOXABL BOXABL Inc. (Nasdaq: BXBL) is transforming the housing market…

FridayAug 28, 2026 9:00 am

BillionDollarBreaks – McEwen Inc. (NYSE: MUX) (TSX: MUX) Announces $240 Million Financing to Advance Los Azules Copper Project

This article has been disseminated on behalf of McEwen Inc. and may include paid advertising. McEwen (NYSE: MUX) (TSX: MUX) announced that its 46.3%-owned subsidiary McEwen Copper Inc. has closed a $240 million senior secured four-year term loan facility to advance engineering and early works at the Los Azules copper project in San Juan, Argentina and for general corporate purposes. Participants include Sprott Natural Resource Investment Partners for $112 million, McEwen Chairman and Chief Owner Rob McEwen for $85 million and other lenders for $43 million. The loan bears interest at 12% annually and provides funding as McEwen Copper works toward a final…

ThursdayAug 27, 2026 9:00 am

BillionDollarBreaks – BOXABL Inc. (NASDAQ: BXBL) Expands Project Development Capabilities With California General Contracting Capacity

BOXABL (NASDAQ: BXBL) announced the expansion of its project development capabilities, including licensed general contracting capacity in California, enabling the modular building company to bid directly on its own site-development and installation projects. The new developer arm expands BOXABL beyond its historical model of manufacturing Casita units while overseeing third-party contractors, giving the company greater ownership of projects from factory through installation. The expanded model is designed to provide individual customers with a more streamlined path covering permitting, site preparation and installation while allowing developers, municipalities and institutional buyers to engage BOXABL directly for broader project delivery, including site evaluation,…

ThursdayAug 13, 2026 9:30 am

BillionDollarBreaks – G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) Reports Q2 Revenue of $157.1 Million, Maintains 2026 Gold Production Guidance

This article has been disseminated on behalf of G Mining Ventures Corp. and may include paid advertising. G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) reported second-quarter 2026 revenue of $157.1 million on sales of 37,439 ounces of gold at an average realized price of $4,197 per ounce. Gold production totaled 36,845 ounces, up 16% sequentially, while net income reached $72 million, or $0.30 per basic share, and free cash flow totaled $84.8 million. The company ended the quarter with $225.7 million in cash and cash equivalents and $33 million in long-term debt, resulting in a net cash position of…

WednesdayJul 29, 2026 9:00 am

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms

VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047. The company said its BiTAC platform is designed to improve the selectivity and…

MondayJul 27, 2026 11:46 am

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures

VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company's outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030 and an increase in the maximum size of the board of directors from five to seven members. The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital…

MondayJul 27, 2026 11:31 am

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration

VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate ("bsADC") program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI). The company said OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an "AND-gate" approach intended to improve precision in treating solid tumors. Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic(TM) platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize…

ThursdayJul 23, 2026 9:30 am

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer

VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development, will lead advancement of the company's proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period. Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the…

MondayJul 20, 2026 9:30 am

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform

VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany's Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The company said the regulatory feedback provides greater clarity on its proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform, representing an early step in advancing the program toward clinical development. VERAXA also highlighted preclinical data presented at the American Association for Cancer Research Annual Meeting 2026 showing its lead BiTAC-TCE candidate selectively targeted cancer cells expressing both intended targets…

The exclusive home of the biggest and brightest companies covered by IBN.

Contact us: (512) 354-7000

Breaks Categories: News